TY - JOUR
T1 - A single dose of granulocyte-macrophage colony-stimulating factor induces systemic interleukin-8 release and neutrophil activation in healthy volunteers
AU - van Pelt, L J
AU - Huisman, M V
AU - Weening, R S
AU - von dem Borne, A E
AU - Roos, D
AU - van Oers, R H
PY - 1996/6/15
Y1 - 1996/6/15
N2 - Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are frequently used in the clinical management of neutropenia. These cytokines not only enhance the proliferation of myeloid precursor cells but also influence the function of mature leukocytes. In a previous study, we found that the in vivo effects of G-CSF on neutrophils differed from those in vitro. In the present study, we investigated the effects of a single dose of recombinant GM-CSF (7.5 microg/kg, subcutaneously) on neutrophils, eosinophils, and monocytes in healthy volunteers. We analyzed leukocyte kinetics, phenotypical changes, neutrophil degranulation, and systemic cytokine production. After GM-CSF injection, phenotypical changes included upregulation of CD11b on all three cell types and a decreased expression of L-selectin and Fc(gamma)RIII on neutrophils. Neutrophil degranulation was evident from the increased plasma concentrations of lactoferrin and elastase. GM-CSF induced the release of interleukin-8 (IL-8), but not of IL-6 or tumor necrosis factor alpha. In comparison to the results from our previous study with G-CSF in healthy volunteers, GM-CSF induced a stronger activation of mature neutrophils but had a much less pronounced effect on the production and maturation of neutrophil precursors. These data may help to guide the choice between the two cytokines in different clinical situations.
AB - Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are frequently used in the clinical management of neutropenia. These cytokines not only enhance the proliferation of myeloid precursor cells but also influence the function of mature leukocytes. In a previous study, we found that the in vivo effects of G-CSF on neutrophils differed from those in vitro. In the present study, we investigated the effects of a single dose of recombinant GM-CSF (7.5 microg/kg, subcutaneously) on neutrophils, eosinophils, and monocytes in healthy volunteers. We analyzed leukocyte kinetics, phenotypical changes, neutrophil degranulation, and systemic cytokine production. After GM-CSF injection, phenotypical changes included upregulation of CD11b on all three cell types and a decreased expression of L-selectin and Fc(gamma)RIII on neutrophils. Neutrophil degranulation was evident from the increased plasma concentrations of lactoferrin and elastase. GM-CSF induced the release of interleukin-8 (IL-8), but not of IL-6 or tumor necrosis factor alpha. In comparison to the results from our previous study with G-CSF in healthy volunteers, GM-CSF induced a stronger activation of mature neutrophils but had a much less pronounced effect on the production and maturation of neutrophil precursors. These data may help to guide the choice between the two cytokines in different clinical situations.
KW - Adult
KW - Cytoplasmic Granules/metabolism
KW - Eosinophils/drug effects
KW - Gene Expression Regulation/drug effects
KW - Granulocyte-Macrophage Colony-Stimulating Factor/administration & dosage
KW - Humans
KW - Immunophenotyping
KW - Injections, Subcutaneous
KW - Interleukin-6/metabolism
KW - Interleukin-8/metabolism
KW - Kinetics
KW - L-Selectin/biosynthesis
KW - Lactoferrin/metabolism
KW - Leukocyte Count/drug effects
KW - Leukocyte Elastase
KW - Macrophage-1 Antigen/biosynthesis
KW - Male
KW - Monocytes/drug effects
KW - Neutrophils/drug effects
KW - Pancreatic Elastase/metabolism
KW - Receptors, IgG/biosynthesis
KW - Recombinant Proteins/administration & dosage
KW - Tumor Necrosis Factor-alpha/metabolism
M3 - Article
C2 - 8652846
SN - 0006-4971
VL - 87
SP - 5305
EP - 5313
JO - Blood
JF - Blood
IS - 12
ER -